NCT02295488 (MAISAVEN) is a NA clinical trial of biological sampling in Hymenoptera Allergy, sponsored by University Hospital, Rouen.

Who is sponsoring NCT02295488?

NCT02295488 is sponsored by University Hospital, Rouen.

What drugs are being tested in NCT02295488?

Interventions in NCT02295488: biological sampling, Desensitization protocol (Alyostall®).

What condition does NCT02295488 study?

NCT02295488 studies Hymenoptera Allergy.

Is NCT02295488 still recruiting?

NCT02295488 is currently completed. Last updated 25 October 2019.

Last reviewed 2019-10-25 · How we verify

NCT02295488: MAISAVEN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Determinism of the Mechanism of Action of Specific Immunotherapy in Hymenoptera Venom Allergy

Completed NA Last updated 25 October 2019

What this trial tests

NA trial testing biological sampling in Hymenoptera Allergy in 29 participants. Completed in 12 April 2018.

Timeline

23 March 2015

Primary endpoint
12 April 2018

12 April 2018

Quick facts

Lead sponsor	University Hospital, Rouen
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	29
Start date	23 March 2015
Primary completion	12 April 2018
Estimated completion	12 April 2018
Sites	1 location across France

Drugs / interventions tested

biological sampling — full drug profile →
Desensitization protocol (Alyostall®) — full drug profile →

Conditions studied

Hymenoptera Allergy — all drugs for Hymenoptera Allergy →

Sponsor

University Hospital, Rouen

Who can join

18 and older, any sex, with Hymenoptera Allergy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, most of the protocols used for desensitization to Hymenoptera venoms consist of a very rapid increase in doses of venom extracts administered during the SIT in a day without systemic reaction of the patient which is not yet explained. The hypothesis is that this good tolerance is due to a rapid decrease in the response of mast cells and basophils to the allergen.. The main objective is to study basophil activation in response to the allergen during the first day of desensitization, measured by basophil activation test. The initiation of desensitization follow a protocol of rapid growth rates. The basophil activation level in the course of desensitization will be analyzed by flow cytometry after in vitro stimulation by allergen. Changes in T cell polarization is also analyzed by flow cytometry. Evolution of the expression of different proteins in blood basophils will be studied by measuring their messenger RNAs

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Adjuvants for allergy immunotherapeutics.
Gamazo C, D'Amelio C, Gastaminza G, Ferrer M, et al · · 2017 · cited 25× · PMID 28825867 · DOI 10.1080/21645515.2017.1348447

Verify or expand the search:

Other trials of biological sampling

Trials testing the same drug.

NCT07081880 — Study of the Pathophysiological Mechanisms Involved in the SAPHO Syndrome: Genetic Component and Immune Response · recruiting
NCT06576622 — PERIodontal Disease, Microbiota and Miscarriage · recruiting
NCT03302884 — Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma · NA · unknown

Other University Hospital, Rouen trials

Trials by the same sponsor.

NCT07441564 — Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Jux · NA · not yet recruiting
NCT07535944 — Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors · not yet recruiting
NCT07464184 — Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension · NA · not yet recruiting
NCT07359885 — Prediction of Postoperative Pulmonary Complications in Thoracic Surgery · not yet recruiting
NCT07247500 — Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02295488 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Rouen
Last refreshed: 25 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02295488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing